Cite
HARVARD Citation
Loftus, E. et al. (n.d.). S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: IBDQ in the SEAVUE Study. American journal of gastroenterology. pp. S355-S357. [Online].